UNITY Biotechnology
285 East Grand Avenue
South San Francisco
CA
94080
United States
Website: https://unitybiotechnology.com/
42 articles about UNITY Biotechnology
-
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
4/23/2024
UNITY Biotechnology, Inc. today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been extended from 24 to 36 weeks to assess potentially greater durability compared to aflibercept.
-
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4/15/2024
UNITY Biotechnology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
-
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
2/6/2024
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nature Medicine that supports the clearance of senescent cells in the retina as a therapeutic approach that can lead to long-term improvements in vision in patients with diabetic macular edema (DME).
-
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMETopline 16-week data expected in the fourth quarter of 2024
12/12/2023
UNITY Biotechnology, Inc. today announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 (foselutoclax), a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema (DME).
-
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
11/13/2023
UNITY Biotechnology, Inc. reported financial results for the third quarter ended September 30, 2023.
-
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
11/10/2023
UNITY Biotechnology, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,143,000 shares of common stock, having an exercise price of $8.50 per share, issued by UNITY on August 22, 2022, at a reduced exercise price of $2.045 per share.
-
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.
-
Unity announced advances in diabetic macular edema via Phase II study results, potentially allowing its recipients to return to tasks of daily living, like driving.
-
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
2/14/2022
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], today announced that 24-week clinical data from the Phase 1 study of UBX1325 was presented by Robert Bhisitkul, M.D., Ph.D., professor of ophthalmology and director of the Retina Fellowship at University of California, San Francisco, at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference on Saturday, February 12, 2022.
-
At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually. And, as is becoming the common scenario, attendees found both pros and cons to our new (temporary?) reality.
-
Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment
12/22/2020
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its licensee, UNITY Biotechnology, has dosed the first patient in a Phase I clinical study of drug candidate UBX1325 in patients with diabetic macular edema.
-
UNITY Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology. As part of the plan, it is decreasing its workforce by about 30% to optimize capital.
-
Clinical Catch-Up: August 17-21
8/24/2020
It was a relatively quiet week for clinical trial news. Here’s a look. -
UNITY Biotechnology reported that the 12-week results from its Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates
5/7/2020
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the first quarter ended March 31, 2020.
-
UNITY Biotechnology, Inc. to Announce First Quarter 2020 Financial Results
5/4/2020
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended March 31, 2020, on Thursday, May 7, 2020 after NASDAQ market close.
-
UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101
3/31/2020
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates related to UBX0101.
-
UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants
3/30/2020
UNITY Biotechnology, Inc. today announced that Anirvan Ghosh, Ph.D., has officially joined the company as Chief Executive Officer.